Physician profile
May Azem
NPI 1407049133
$75,175.66
in general payments reported to CMS, 2019-2025
45 companies · $9,832 in 2025
The $9,832 reported for 2025 was more than what 90% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $16K · 2021: $11K · 2022: $5,038 · 2023: $5,045 · 2024: $5,076 · 2025: $9,832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Consulting Fee: $2,280 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,320 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,193.24 |
| Consulting Fee | $2,280.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,320.00 |
| Education | $159.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $30,408.28 | 2019-2025 | Taltz, Omvoh, Olumiant |
| Janssen Biotech, INC. | $10,758.58 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Novartis Pharmaceuticals Corporation | $7,801.39 | 2019-2025 | |
| Amgen INC. | $4,727.77 | 2019-2025 | Enbrel, Evenity, Prolia |
| Abbvie INC. | $3,959.86 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $3,132.96 | 2019-2025 | Cimzia, Bimzelx |
| Mallinckrodt Hospital Products INC. | $2,562.96 | 2020-2025 | Acthar |
| Pfizer INC. | $1,776.41 | 2019-2025 | |
| Genentech USA, INC. | $1,634.85 | 2019-2025 | Actemra, Gazyva |
| Ani Pharmaceuticals, INC. | $1,209.06 | 2022-2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $1,080.75 | 2019-2025 | Orencia, Sotyktu |
| Horizon Therapeutics Plc | $1,038.29 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $662.70 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals Lp | $472.46 | 2023-2025 | Saphnelo |
| Radius Health, INC. | $413.75 | 2019-2025 | Tymlos |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw May Azem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.